Company Profile for Trevena, Inc.

Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of GPCR targeted medicines. Trevena's oliceridine is in Phase 3 development for the management of moderate to severe acute pain, and is the first pain program granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.

   

Company:

Trevena, Inc.

 

Headquarters Address:

1018 West 8th Ave, Suite A
King of Prussia, PA 19406
 

Main Telephone:

610-354-8840
 

Website:

www.trevena.com

 

Ticker/ISIN:

TRVN(NASDAQ)/US89532E1091
 

Type of Organization:

Public
 

Industry:

Biotechnology
 

Key Executives:

CEO: Maxine Gowen

 

Investor Relations

Contact:

Jonathan Violin

Phone:

610-534-8840

Email:

IR@trevenainc.com

 

Source: Trevena, Inc.